Evaluation of platelet activation, coagulation, and fibrinolytic activation in patients with symptomatic lacunar stroke

Neurologist

Volumn 16, Issue 3, 2010, Pages 188-191

  Ilhan, Demet ^a   Özbabalik, Demet ^a   Gulcan, Erim ^a   Özdemir, Özcan ^a   Gülbaçs, Zafer ^a  

^a DUMLUPINAR UNIVERSITY   (Turkey)

Author keywords

Coagulation; Fibrinolytic activation; Platelet activation; Symptomatic lacunar stroke

Indexed keywords

D DIMER; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOCYTE FACTOR 4;

AGED; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; BRAIN INFARCTION; BRAIN ISCHEMIA; CARBOXYPEPTIDASE U; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ACTIVATION; PLATELET FACTOR 4; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 77952083898     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e318198d8bc     Document Type: Article

References (39)

1. Ohara T, Yamamoto Y, Oiwa K, et al. Clinical classification for lacunar infarct. An investigation of 130 consecutive cases of lacunar infarctions. Rinsho Shinkeigaku. 2005; 45: 6-12.
2. Lindenstrom E, Boysen G, Nyobe J. Risk factors for stroke in Copenhagen, Denmark. Part I. N Engl J Med. 1992; 326: 242-250.
3. Graeves M. Coagulation abnormalities and cerebral infarction. J Neurol Neurosurg Psychiatry. 1993; 56: 433-439.
4. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. Stroke. 1990; 2: 1111-1121.
5. Weksler BB. Hematologic disease and ischemic stroke. Curr Opin Neurol. 1995; 8: 38-34.
6. Adams HP, Bebdixen BH, Kapelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35-41.
7. Demarmels Biasiutti F, Berger D, Mattle HP, et al. Hemostatic risk factors in ischemic stroke. Thromb Haemost. 2003; 90: 1094-1099.
8. Schultz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke. Importance of population based studies. Stroke. 2003; 34: 2050-2059.
9. Arboix A, Morcillo C, Garcia-Eroles L, et al. Different vascular risk faktor profiles in ischemic stroke subtypes: a study from the 'Sagrat Cor Hospital of Barcelona Stroke Registry.' Acta Neurol Scand. 2000; 102: 264-270.
10. Grau AJ, Weimar C, Buggle F, et al; For the German stroke Data Bank Collaborators. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German Stroke Data Bank. Stroke. 2001; 32: 2559-2566.
11. Barber M, Langhorne P, Rumley A. Hemostatic function and progressing ischemic stroke. D-dimer predicts early clinical progression. Stroke. 2004; 35: 1421.
12. Yamamoto Y, Oiwa K, Hayashi M, et al. Coagulation and fibrinolytic activation in lacunar infarct patients. Rinsho Shinkeigaku. 1999; 39: 1104-1108.
13. Kataoka S, Hirose G, Hori A, et al. Activation of thrombosis and fibrinolysis following brain infarction. J Neurol Sci. 2000; 181: 82-88.
14. Yamazaki M, Uchiyama S, Maruyama S. Alterations of haemostatic markers in various subtypes and phases of stroke. Blood Coag Fibrinolysis. 1993; 4: 707-712.
15. Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002; 117: 399-404.
16. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol. 1992; 14: 281-287.
17. Bath PM, Butterworth RJ. Platelet size: measurement, physiology, and vascular disease. Blood Coagul Fibrinolysis. 1996; 7: 157-161.
18. MacGregor GA. Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci (Lond). 1994; 87: 253-257.
19. D'Erasmo E, Aliberti G, Celi FS, et al. Platelet count, mean platelet volume, and their relation to prognosis in cerebral infarction. J Intern Med. 1990; 227: 11-14.
20. O'Malley T, Langhorne P, Elton RA, et al. Platelet size in stroke patients. Stroke. 1995; 26: 995-999.
21. Greisenegger S, Endler G, Hsieh K, et al. Elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke. 2004; 35: 1688.
22. McCabe DJ, Harrison P, Sidhu PS, et al. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol. 2004; 126: 861-869.
23. Santamaria A, Oliver A, Borrell M, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke. 2003; 34: 2387.
24. Montaner J, Ribó M, Monasterio J, et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003; 34: 1038.
25. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol. 1990; 47: 1075-1079.
26. Feinberg WM, Bruck DC, Jeter MA, et al. Fibrinolysis after acute ischemic stroke. Thromb Res. 1991; 64: 117-127.
27. Beslac-Bumbasirevic L, Kostic VS. Plasminogen activator inhibitor-1 in the evolution of stroke. Srp Arh Celok Lek. 2004; 132: 143-147.
28. Lindgren A, Lindoff C, Noorving B, et al. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke. 1996; 27: 1066-1071.
29. Haapaniemi E, Tatlisumak T, Soinne L, et al. Plasminogen activator inhibitor-1 in patients with ischemic stroke. Acta Neurochir Suppl. 2000; 76: 277-278.
30. Tohgi H, Takahashi H, Chiba K, et al. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke. 1993; 24: 801-804.
31. Sandercock P, Gubitz G, Foley P, et al. Antiplatelet therapy for acute ischemic stroke. Cochrane Database Syst Rev. 2003; 2: CD000029.
32. Minuz P, Patrignani P, Gaino S, et al. Determinants of platelet activation in human essential hypertension. Hypertension. 2004; 43: 64-70.
33. Cherian P, Hankey GJ, Eikelboom JW, et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke. 2003; 34: 2132.
34. Fassbender K, Bertsch T, Mielke O, et al. Circulating selectin-and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke. 1995; 26: 1361-1364.
35. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol. 1990; 47: 1075-1079.
36. Woo E, Huang C, Chan V, et al. Beta-thromboglobulin in cerebral infarction. J Neurol Neurosurg Psychiatry. 1988; 51: 557-562.
37. Shyu KG, Chang H, Lin CC. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischemic stroke. J Neurol. 1997; 244: 90-93.
38. Nagao T, Hamamoto M, Kanda A, et al. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. Stroke. 1995; 26: 1365-1368.
39. Landi G, D'Angelo A, Boccardi E, et al. Hypercoagulability in acute stroke: prognostic significance. Neurology. 1987; 37: 1667-1671.